Expanding our knowledge of dry AMD

Article

Professor Scott Cousins explains how we can use our knowledge of drusen formation to find new ways to combat dry age-related macular degeneration.

Key Points

Drusen development: the four theories

Currently, there are four key theories for explaining drusen formation. These are:

The role of inflammation

Our understanding of the disease has evolved rapidly in recent years. "I think that the greatest breakthrough in understanding the pathogenesis of drusen that we have had in the last five to seven years is this idea that inflammation, in various forms, is a major contributor to the disease; that the innate immune system plays a major role," asserted Professor Cousins. "In the last three years, there has been a lot of data published that show that the genetic impetus of AMD is found among the complement inhibitors in the complement system; specifically, Complement Factor H is the most important susceptibility gene.

"My laboratory, among others, has also looked at the role of one of the circulating white cells: the monocyte. We already know that its tissue equivalent, the macrophage, has a major role to play in wet AMD, but we're now learning it plays a role in dry AMD as well, and so we're exploring what this may mean for the development of the disease," Professor Cousins explained.

"The most recent breakthrough in our understanding was published in a New England Journal of Medicine article,"1 Professor Cousins continued. As previously reported by Ophthalmology Times Europe,2 this study examined the role of a mutation of the toll-like receptor 3 (TLR3) gene. TLR3 is a protein that alerts the immune system to infections, and a mutated form of the TLR3 gene, expressing leucine instead of phenylalanine, was shown to be protective against geographic atrophy, most likely by suppressing the death of RPE cells.

Recent Videos
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Related Content
© 2024 MJH Life Sciences

All rights reserved.